|Bid||113.00 x 1800|
|Ask||113.10 x 3000|
|Day's Range||112.74 - 113.33|
|52 Week Range||108.12 - 155.12|
|PE Ratio (TTM)||N/A|
|YTD Daily Total Return||-21.73%|
|Beta (5Y Monthly)||2.47|
|Expense Ratio (net)||0.15%|
TORONTO, April 05, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDC”) 1 and their associated drug formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, has provided an update on the Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC“) Clinical Study (“Stud
Jason England, Global Bonds Portfolio Manager at Janus Henderson Investors, joins Yahoo Finance to talk Fed policy.
Yahoo Finance's Brian Cheung details the Federal Reserve's last announcement of 2021.